American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Clinical Oncology

• Publication date

  1999-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1999.17.10.3333PMID 10506637
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders

  2005cited by this paper
• A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration

  2005cited by this paper
• Decreased plasma half-life of cyclophosphamide during repeated high-dose administration

  2004cited by this paper
• High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma

  2004cited by this paper
• 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

  2000cited by this paper
• Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.

  1999cited by this paper
• Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.

  1998cited by this paper
• Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.

  1998cited by this paper
• Cost-utility assessment of amifostine as first-line therapy for ovarian cancer

  1998cited by this paper
• Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.

  1998cited by this paper
• Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.

  1997cited by this paper
• Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy

  1997cited by this paper
• Randomized phase III trial of radiation±Ethyol® (Amifostine) in patients with head and neck cancer

  1997cited by this paper
• Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

  1997cited by this paper
• Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients.

  1997cited by this paper
• Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.

  1997cited by this paper
• Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors

  1997cited by this paper
• Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.

  1997cited by this paper
• Late cardiotoxicity after treatment for a malignant bone tumor.

  1996cited by this paper
• Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.

  1996cited by this paper
• High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.

  1996cited by this paper
• Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.

  1996cited by this paper
• Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.

  1996cited by this paper
• Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.

  1996cited by this paper
• Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.

  1996cited by this paper
• Cardiac function in Wilms' tumor survivors.

  1995cited by this paper
• High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.

  1995cited by this paper
• Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

  1995cited by this paper
• Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.

  1995cited by this paper
• Efficacy of Mesna for Prevention of Hemorrhagic Cystitis After High-Dose Cyclophosphamide Therapy

  1995cited by this paper
• Frequent Short-Term Oral Complications of Head and Neck Radiotherapy

  1994cited by this paper
• American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.

  1994cited by this paper
• Genetic toxicity and potential carcinogenicity of taxol.

  1994cited by this paper
• Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.

  1994cited by this paper
• Increased risk of cardiac dysfunction after anthracyclines in girls.

  1993cited by this paper
• Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial.

  1993cited by this paper
• Neurotoxicity of Taxol.

  1993cited by this paper
• Amifostine‐mediated protection of normal bone marrow from cytotoxic chemotherapy

  1993cited by this paper
• Use of radiation with or without WR‐2721 in advanced rectal cancer

  1992cited by this paper
• ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

  1992cited by this paper
• Rules of evidence and clinical recommendations on the use of antithrombotic agents.

  1992cited by this paper
• Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.

  1992cited by this paper
• Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

  1991cited by this paper
• Bladder irrigation does not prevent haemorrhagic cystitis in bone marrow transplant recipients.

  1991cited by this paper
• Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation.

  1991cited by this paper
• Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

  1991cited by this paper
• Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

  1991cited by this paper
• High-dose ifosfamide with mesna uroprotection: a phase I study.

  1990cited by this paper
• Rules of evidence and clinical recommendations on the use of antithrombotic agents.

  1989cited by this paper
• Rules of evidence and clinical recommendations on the use of antithrombotic agents.

  1989cited by this paper
• Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course, and outcome.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Chemical modifiers of cancer treatment.

  1988cited by this paper
• Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug.

  1988cited by this paper
• Cisplatin neuropathy. Risk factors, prognosis, and protection by WR‐2721

  1988cited by this paper
• Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.

  1988cited by this paper
• The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.

  1987cited by this paper
• Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.

  1987cited by this paper
• Ifosfamide — Dosing and Scheduling

  1987cited by this paper
• Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.

  1987cited by this paper
• WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.

  1987cited by this paper
• Phase II trial of ifosfamide and mesna in advanced colorectal cancer.

  1987cited by this paper
• Human pharmacokinetics of WR-2721.

  1986cited by this paper
• The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.

  1986cited by this paper
• WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.

  1986cited by this paper
• Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.

  1985cited by this paper
• Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study.

  1984cited by this paper
• Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity

  1984cited by this paper
• Phase I trials of WR-2721 and cis-platinum.

  1984cited by this paper
• High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.

  1983cited by this paper
• Book ReviewInternal Medicine

  1983cited by this paper
• Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas.

  1983cited by this paper
• Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.

  1983cited by this paper
• Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.

  1983cited by this paper
• Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent).

  1983cited by this paper
• Efficacy and cost of cardiac monitoring in patients receiving doxorubicin

  1982cited by this paper
• Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

  1982cited by this paper
• Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).

  1982cited by this paper
• Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.

  1982cited by this paper
• Clinical trials of WR-2721 with radiation therapy.

  1982cited by this paper
• Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity.

  1982cited by this paper
• Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.

  1981cited by this paper
• [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].

  1981cited by this paper
• Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.

  1980cited by this paper
• Hepatic irradiation and adriamycin cardiotoxicity.

  1979cited by this paper
• Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.

  1979cited by this paper
• Decreased half life of cyclophosphamide in patients under continual treatment.

  1979cited by this paper
• The periodic health examination. Canadian Task Force on the Periodic Health Examination.

  1979cited by this paper
• Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.

  1979cited by this paper
• Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.

  1979cited by this paper
• Risk factors for doxorubicin-induced congestive heart failure.

  1979cited by this paper
• Serial studies of cardiac function in patients receiving adriamycin.

  1978cited by this paper
• Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients.

  1978cited by this paper
• Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.

  1978cited by this paper
• Age-related adriamycin cardiotoxicity in children.

  1978cited by this paper
• High incidence of cardiomyopathy in children treated with adriamycin and DTIC in combination chemotherapy.

  1977cited by this paper
• Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity

  1977cited by this paper
• Adriamycin cardiotoxicity in children. Case reports, literature review, and risk factors

  1977cited by this paper
• Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.

  1976cited by this paper
• Pharmacokinetics of divided‐dose ifosfamide

  1976cited by this paper

• Caught in the crossfire: cardiac complications of cancer therapy

  2026cites this paper
• Cytotoxic Effects of Herbal Medicine: An Overview of Mechanistic Pathways and Clinical Relevance

  2025cites this paper
• Quantitative assessment of damage and radioprotection in primary human bronchial epithelial cells exposed to distinct ionizing radiation types

  2025cites this paper
• An expert consensus on prevention, diagnosis, and management of hemorrhagic cystitis in pediatric hematopoietic cell transplantation, on behalf of the Infectious Disease and Hematopoietic Cell Transplant Working groups of Italian Pediatric Hematology Oncology Association (AIEOP)

  2024cites this paper
• Position statement of the Brazilian society of Rheumatology on mesna use as a preventive therapy for bladder disease in patients with systemic autoimmune diseases and systemic vasculitis under cyclophosphamide treatment

  2024cites this paper
• Acetyl tributyl citrate attenuates 5-fluorouracil-induced inflammation, oxidative stress, and apoptosis in human keratinocytes.

  2024cites this paper
• Discovery of anticancer peptides from natural and generated sequences using deep learning.

  2024cites this paper
• Aucubin alleviates doxorubicin-induced cardiotoxicity through crosstalk between NRF2 and HIPK2 mediating autophagy and apoptosis.

  2024cites this paper
• Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

  2023cites this paper
• Oral Maxillofacial Surgeon – A Hidden Weapon in Head and Neck Oncology

  2023cites this paper
• Genoprotective Effect of Some Flavonoids against Genotoxic Damage Induced by X-rays In Vivo: Relationship between Structure and Activity

  2021cites this paper
• Cyclophosphamide-induced inflammation of taste buds and cytoprotection by amifostine.

  2021cites this paper
• Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration.

  2021cites this paper
• Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.

  2021cites this paper
• Cisplatin-induced renal toxicity in elderly people

  2020cites this paper
• Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine

  2020cites this paper
• Radioprotective profile of Urtica dioica L. seed extract on oxidative DNA-damage in liver tissue and whole blood of radiation-administered rats

  2020cites this paper
• Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: A cohort study and comprehensive literature review

  2020cites this paper
• Novel potassium binders as enabling therapy in heart failure

  2019cites this paper
• Chemical Profiling of Polyphenolics in Eucalyptus globulus and Evaluation of Its Hepato–Renal Protective Potential Against Cyclophosphamide Induced Toxicity in Mice

  2019cites this paper
• Managing a side effect: Cyclophosphamide-induced hemorrhagic cystitis

  2019cites this paper
• Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide

  2018cites this paper
• Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer

  2018cites this paper
• The impact of squalene on disease models

  2018cites this paper
• Randomized double‐blind trial of amifostine versus placebo for radiation‐induced xerostomia in patients with head and neck cancer

  2018cites this paper
• Cyclophosphamide‐induced hemorrhagic cystitis in young patients with solid tumors: A single institution study

  2018cites this paper
• Survivin as a novel target protein for reducing the proliferation of cancer cells.

  2018cites this paper
• Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival

  2018cites this paper
• Bladder Sarcomatoid Carcinoma in an Adolescent: 10-Year Survival After Aggressive Surgical Management

  2018cites this paper
• Effects of traditional oriental medicines as anti-cytotoxic agents in radiotherapy.

  2017cites this paper
• Radioprotective Effect of Vitamin C as an Antioxidant

  2017cites this paper
• Real-time measurement of small molecules directly in awake, ambulatory animals

  2017cites this paper
• Potential Protective Effects of Ursolic Acid against Gamma Irradiation-Induced Damage Are Mediated through the Modulation of Diverse Inflammatory Mediators

  2017cites this paper
• Ferulic acid (FA) abrogates γ-radiation induced oxidative stress and DNA damage by up-regulating nuclear translocation of Nrf2 and activation of NHEJ pathway

  2017cites this paper
• Chapter 40 – Preventive Therapy

  2017cites this paper
• Improving aspects of palliative care for children

  2017cites this paper
• The effect of Amifostine, in chemotherapy, radiotherapy, as potential Cytoprotectant, and Immunomodulatory, in Cancer and Autoimmunity Treatment and Prevention

  2017cites this paper
• Interventions for preventing hemorrhagic cystitis in patients undergoing hematopoietic stem cell transplantation

  2016cites this paper
• Cardiotoxicity in anthracycline therapy: Prevention strategies☆

  2016influential citation
• A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.

  2016cites this paper
• Curculigo orchioides Gaertn Effectively Ameliorates the Uro- and Nephrotoxicities Induced by Cyclophosphamide Administration in Experimental Animals

  2016cites this paper
• Radioprotective Effects of Amifostine and Lycopene on Human Peripheral Blood Lymphocytes In Vitro.

  2016cites this paper
• 93 1 , 4-Naphthoquinone , a pro-oxidant , ameliorated radiation induced gastro-intestinal injury through perturbation of cellular redox and activation of Nrf 2 pathway

  2016cites this paper
• Radioprotective Effect of Epigallocatechin-3-Gallate on Salivary Gland Dysfunction After Radioiodine Ablation in a Murine Model

  2016cites this paper
• Estrategias de prevención de cardiotoxicidad Preventive strategies of cardiotoxicity

  2016cites this paper
• Radioprotective Agents: Strategies and Translational Advances

  2016cites this paper
• Strategies to Overcome Late Complications from Radiotherapy for Childhood Head and Neck Cancers.

  2016cites this paper
• 1,4-Naphthoquinone, a pro-oxidant, ameliorated radiation induced gastro-intestinal injury through perturbation of cellular redox and activation of Nrf2 pathway.

  2016cites this paper
• Predictors for severe acute esophagitis in lung cancer patients treated with chemoradiotherapy: a systematic review

  2016cites this paper
• Cardiotoxicity in anthracycline therapy: Prevention strategies.

  2016cites this paper
• Cyclophosphamide and ifosfamide: mechanisms of cytotoxic action and consequences for normal bladder function.

  2015cites this paper
• Common Oncological Emergencies

  2015cites this paper
• Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases

  2015cites this paper
• Anthracycline-Induced Cardiomyopathy in Adults.

  2015cites this paper
• Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties.

  2015cites this paper
• The management of residual or recurrent central neurocytoma.

  2015cites this paper
• Impact of a multifaceted education program on implementing a pediatric palliative care guideline: a pilot study

  2015cites this paper
• XEROSTOMIA IN GERIATRIC POPULATION: AN INSIGHT INTO ETIOPATHOGENESIS, DIAGNOSIS AND MANAGEMENT

  2015cites this paper
• AKCİĞER KANSERİ VE NEFROLOJİK HASTALIKLAR LUNG CANCER AND NEPHROLOGIC DISEASES

  2015cites this paper
• Chemotherapy - Induced Cardiotoxicity

  2015cites this paper
• A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma

  2015cites this paper
• Treatment of Irradiated Mice with High-Dose Ascorbic Acid Reduced Lethality

  2015cites this paper
• Prevention of cyclophosphamide-induced hemorrhagic cystitis by resveratrol: a comparative experimental study with mesna

  2014cites this paper
• Nano-based drug delivery modalities for the treatment of cancer: The formulation of tumour-specific and-targeted nanoparticles

  2014cites this paper
• Targeting the Renin-angiotensin system combined with an antioxidant is highly effective in mitigating radiation-induced lung damage.

  2014cites this paper
• Evidence-Based Practice Recommendations for Hydration in Children and Adolescents With Cancer Receiving Intravenous Cyclophosphamide

  2014cites this paper
• Role of Ferulic Acid in the Amelioration of Ionizing Radiation Induced Inflammation: A Murine Model

  2014cites this paper
• Effect of hydrophobicity of core on the anticancer efficiency of micelles as drug delivery carriers.

  2014cites this paper
• The Beneficial Effects of a Supersaturated Calcium Phosphate Rinse on the Oral Cavity in Xerostomia Patients

  2014cites this paper
• Systemic therapy of metastatic breast cancer

  2014cites this paper
• Seabuckthron (Hippophae rhamnoides L.) leaf extract ameliorates the gamma radiation mediated DNA damage and hepatic alterations.

  2014cites this paper
• Renal Adverse Effect in Sold Cancer Patients Treated With Cytotoxic Agents

  2014cites this paper
• Mitigation of Radiation-Induced Damage by Targeting EGFR in Noncancerous Human Epithelial Cells

  2013cites this paper
• Modulatory role of quercetin against gamma radiation-mediated biochemical and morphological alterations of red blood cells

  2013cites this paper
• Pre-Treatment with Amifostine Protects against Cyclophosphamide-Induced Disruption of Taste in Mice

  2013cites this paper
• Gossypetin, a naturally occurring hexahydroxy flavone, ameliorates gamma radiation-mediated DNA damage

  2013cites this paper
• Activity of Dexrazoxane and Amifostine Against Late Cardiotoxicity Induced by the Combination of Doxorubicin and Cyclophosphamide In Vivo

  2013cites this paper
• Effects of tyrosine kinase inhibitors on rat isolated heart function and protein biomarkers indicative of toxicity.

  2013cites this paper
• Relationship of Grade of Malignant Brain Tumor to Cancer Stem Cells and Survivin Expression

  2013cites this paper
• Renal Disease in Cancer Patients

  2013cites this paper
• The Cytoprotective Effect of Amifostine Against Radiation Induced Toxicity

  2012influential citation
• Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer

  2012cites this paper
• Prevention of radiation‐induced xerostomia by submandibular gland transfer

  2012cites this paper
• Quantitative Histologic Evidence of Amifostine-Induced Cytoprotection in an Irradiated Murine Model of Mandibular Distraction Osteogenesis

  2012cites this paper
• Amifostine

  2012cites this paper
• Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation

  2012cites this paper
• Neuropathy Secondary to Chemotherapy: A Real Issue for Cancer Survivors

  2012cites this paper
• Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines.

  2012cites this paper
• Radioiodine-induced kidney damage and protective effect of amifostine: An experimental study.

  2012cites this paper
• Bladder cancer risk from occupational and environmental exposures.

  2012cites this paper
• Mitigation of Radiation-Induced Lung Injury with EUK-207 and Genistein: Effects in Adolescent Rats

  2012cites this paper
• CURENT ADVANCES AND STRETEGIES FOR REDUCING THE SIDE EFFECTS OF RADIATION THERAPIES USED FOR VARIOUS TYPES OF CANCERS

  2012cites this paper
• Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.

  2012cites this paper
• The histopathological comparison of L-carnitine with amifostine for protective efficacy on radiation-induced acute small intestinal toxicity.

  2012cites this paper
• Local Hemodynamic Effects of Radiation on the Rabbit Orbitozygomatic Complex with and without Cytoprotection

  2012cites this paper
• Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.

  2012cites this paper
• Development of a UPLC-ESI-MS/MS method for the determination of larotaxel in beagle dog plasma: application to the pharmacokinetic study

  2012cites this paper
• Cardiotoxicity of Oncological Treatment in Children Kardiotoksyczność leczenia onkologicznego u dzieci

  2012cites this paper
• Amifostine Remediates the Degenerative Effects of Radiation on the Mineralization Capacity of the Murine Mandible

  2012cites this paper
• Cardiotoxicity of oncological treatment in children.

  2012cites this paper